The 10Q is not all that bad IMO.3Q03 vs 3Q02 shows 35% total revenue increase. And 25% increase of Net Income (after everything). Cash flow from operations continues to increase nicely. (9 months 2003 is $368M vs $325M 9 months 02. The Elan purchase should have a pretty huge effect on sales going forward as the 2002 sales of the Elan products (Sonata, Skelaxin) amounted to $238 million. A big charge they took on the Elan purchase was Research in progress amounting to $193M.KG is not a big research (viz. expensive) company. R&D amounted to 2% of sales in 3Q03. Their stated emphasis (see 3Q03 conf call) is to acquire other properties (drugs) and drive growth that way.I view their diversified drug portfolio a plus. The more SKUs you have selling the less likely one drop in a line is going to affect your total business. (Ditto with stock portfolios, no?)Pros:Big margins, excellent growth.Demographics - increasing drug consumption (geezers)No 'big pharma' R&D overhead.Strong, invested, growth-oriented leadership.Increased sales team from Elan purchase.Cons:Continuing SEC, et al. investigation into Medicaid rebates.General uncertainty re Medicare program government proposals.Lack of visibility of inventory flow (conf call).80% Institutional ownership.Summary: if you stand back and look at what this young growth company has done and is doing now I think you will find excellent value. It is trading at a pretty low price for what it has achieved. If management keeps its eye on the ball, and government doesn't totally muck up the industry, this should be a superlative 3-5+ year holding. Phil [long KG]
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat